Biotech Values

[DewDiligence]

That’s a standout adage! What ICPT is doing looks like a variant on Zebra’s Law. I.e., ICPT has an approved drug (Ocaliva for PBC), but the approved indication is too narrow for the company to become profitable. Hence, ICPT continues to seek Ocaliva approval for NASH despite the drug’s utter unsuitability for that indication.